Annovis Bio Inc (ANVS)
8.29
+0.26
(+3.24%)
USD |
NYSE |
May 17, 16:00
8.30
+0.01
(+0.12%)
Pre-Market: 20:00
Annovis Bio Research and Development Expense (Quarterly): 6.515M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 6.515M |
| December 31, 2023 | 8.905M |
| September 30, 2023 | 13.84M |
| June 30, 2023 | 8.262M |
| March 31, 2023 | 7.786M |
| December 31, 2022 | 6.208M |
| September 30, 2022 | 4.124M |
| June 30, 2022 | 4.034M |
| March 31, 2022 | 2.150M |
| December 31, 2021 | 2.884M |
| September 30, 2021 | 1.381M |
| June 30, 2021 | 1.824M |
| March 31, 2021 | 2.390M |
| Date | Value |
|---|---|
| December 31, 2020 | 1.412M |
| September 30, 2020 | 0.7189M |
| June 30, 2020 | 0.8565M |
| March 31, 2020 | 0.0664M |
| December 31, 2019 | 0.7622M |
| September 30, 2019 | 0.002M |
| June 30, 2019 | 0.006M |
| March 31, 2019 | 0.006M |
| December 31, 2018 | 0.0133M |
| September 30, 2018 | 0.0133M |
| June 30, 2018 | 0.0272M |
| March 31, 2018 | 0.0578M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.002M
Minimum
Sep 2019
13.84M
Maximum
Sep 2023
3.706M
Average
2.270M
Median
Research and Development Expense (Quarterly) Benchmarks
| ANI Pharmaceuticals Inc | 10.51M |
| Ligand Pharmaceuticals Inc | 5.971M |
| FibroGen Inc | 38.39M |
| SINTX Technologies Inc | 2.019M |
| Stereotaxis Inc | 2.243M |